New Treatment For Advanced HER2+ Breast Cancer Patients As Perjeta® (Pertuzumab) Gets
 

Perjeta works synergistically with Herceptin® (trastuzumab) to extend survival and stall disease progression for longer than the gold standard of care[i] From now on, patients with advanced HER2-positive breast cancer could benefit from the new personalised breast cancer treatment, Perjeta - which is now authorised for use in the UK...

More...